# Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

> **NCT04213222** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Colon Cancer
- Rectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04213222
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10
- **Primary completion:** 2022-06
- **Final completion:** 2023-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213222, "Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04213222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*